Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could

Latest news

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing

  • Praluent can stay on market for now, says US court Praluent can stay on market for now, says US court

    Praluent was approved in the US first, but Amgen has so far won the key rounds in the legal dispute over PCSK9 inhibitor intellectual property rights. ... This decision is important for patients in the US who will continue to have access to Praluent

  • New outcomes data could unlock Repatha's potential, says Amgen New outcomes data could unlock Repatha's potential, says Amgen

    PCSK9 inhibitor Repatha (evolocumab) was approved on the strength of data showing it could reduce low-density lipoprotein cholesterol (LDL-c), but health insurers and pharmacy benefit managers in the US ... for their rival PCSK9 inhibitor Praluent

  • Amgen wins block on sales of Sanofi/Regeneron's Praluent Amgen wins block on sales of Sanofi/Regeneron's Praluent

    Amgen has won another round in its lawsuit with Sanofi and Regeneron over patent rights to the new PCSK9 inhibitor class of cholesterol-lowering drugs. ... The decision follows an earlier victory for Amgen as it defended patents on its rival PCSK9

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    Amgen's Repatha unclogs blocked arteries, says study. Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins. ... Despite blockbuster sales projections, PCSK9 inhibitor Repatha (evolocumab) and rival drug Praluent

More from news
Approximately 10 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics